Overview of the STAT‑3 signaling pathway in cancer and the development of specific inhibitors (Review)
- Authors:
- Yuchen Gu
- Imran Shair Mohammad
- Zhe Liu
-
Affiliations: Department of Pharmacy, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233000, P.R. China, School of Pharmaceutical Sciences, Sun Yat‑Sen University, Guangzhou, Guangdong 510006, P.R. China - Published online on: February 13, 2020 https://doi.org/10.3892/ol.2020.11394
- Pages: 2585-2594
-
Copyright: © Gu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Levy DE and Darnell JE Jr: Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol. 3:651–662. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Schindler C, Levy DE and Decker T: JAK-STAT signaling: From interferons to cytokines. J Biol Chem. 282:20059–20063. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Reich NC and Liu L: Tracking STAT nuclear traffic. Nat Rev Immunol. 6:602–612. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Stark GR and Darnell JE Jr: The JAK-STAT pathway at twenty. Immunity. 36:503–514. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yu H, Pardoll D and Jove R: STATs in cancer inflammation and immunity: A leading role for STAT-3. Nat Rev Cancer. 9:798–809. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bromberg J and Darnell JE Jr: The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 19:2468–2473. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Darnell JE Jr: STATs and gene regulation. Science. 277:1630–1635. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Buettner R, Mora LB and Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 8:945–954. 2002.PubMed/NCBI | |
|
Yu H and Jove R: The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Haura EB, Turkson J and Jove R: Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol. 2:315–324. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Herrmann A, Kortylewski M, Kujawski M, Zhang C, Reckamp K, Armstrong B, Wang L, Kowolik C, Deng J, Figlin R and Yu H: Targeting STAT3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res. 70:7455–7464. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kortylewski M and Yu H: Role of STAT-3 in suppressing anti-tumor immunity. Curr Opin Immunol. 20:228–233. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H and Yu H: STAT-3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest. 118:3367–3377. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D and Yu H: IL-17 can promote tumor growth through an IL-6-STAT-3 signaling pathway. J Exp Med. 206:1457–1464. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG, et al: Inhibiting STAT3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 11:1314–1321. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Yu H, Kortylewski M and Pardoll D: Crosstalk between cancer and immune cells: Role of STAT-3 in the tumour microenvironment. Nat Rev Immunol. 7:41–51. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Nowak EM, Poczęta M, Bieg D and Bednarek I: DNA methyltransferase inhibitors influence on the DIRAS3 and STAT3 expression and in vitro migration of ovarian and breast cancer cells. Ginekol Pol. 88:543–551. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yu H, Lee H, Herrmann A, Buettner R and Jove R: Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Mali SB: Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancer. Oral Oncol. 51:565–569. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Benekli M, Baer MR, Baumann H and Wetzler M: Signal transducer and activator of transcription proteins in leukemias. Blood. 101:2940–2954. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Calò V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N and Russo A: STAT proteins: From normal control of cellular events to tumorigenesis. J Cell Physiol. 197:157–168. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Sternberg DW and Gilliland DG: The role of signal transducer and activator of transcription factors in leukemogenesis. J Clin Oncol. 22:361–371. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Abroun S, Saki N, Ahmadvand M, Asghari F, Salari F and Rahim F: STATs: An old story, yet mesmerizing. Cell J. 17:395–411. 2015.PubMed/NCBI | |
|
Yang E, Henriksen MA, Schaefer O, Zakharova N and Darnell JE Jr: Dissociation time from DNA determines transcriptional function in a STAT1 linker mutant. J Biol Chem. 277:13455–13462. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Wake MS and Watson CJ: STAT3 the oncogene-still eluding therapy? FEBS J. 282:2600–2611. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Huang Y, Qiu J, Dong S, Redell MS, Poli V, Mancini MA and Tweardy DJ: Stat3 isoforms, alpha and beta, demonstrate distinct intracellular dynamics with prolonged nuclear retention of Stat3beta mapping to its unique C-terminal end. J Biol Chem. 282:34958–34967. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chakraborty A, Dyer KF, Cascio M, Mietzner TA and Tweardy DJ: Identification of a novel STAT-3 recruitment and activation motif within the granulocyte colony-stimulating factor receptor. Blood. 93:15–24. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Chakraborty A and Tweardy DJ: STAT-3 and G-CSF-induced myeloid differentiation. Leuk Lymphoma. 30:433–442. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Ilaria RL Jr: STAT isoforms: Mediators of STAT specificity or leukemogenesis? Leuk Res. 25:483–484. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Huynh J, Chand A, Gough D and Ernst M: Therapeutically exploiting STAT3 activity in cancer-using tissue repair as a road map. Nat Rev Cancer. 19:82–96. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chai EZ, Shanmugam MK, Arfuso F, Dharmarajan A, Wang C, Kumar AP, Samy RP, Lim LH, Wang L, Goh BC, et al: Targeting transcription factor STAT3 for cancer prevention and therapy. Pharmacol Ther. 162:86–97. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
ten Hoeve J, de Jesus Ibarra-Sanchez M, Fu Y, Zhu W, Tremblay M, David M and Shuai K: Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol. 22:5662–5668. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Shuai K and Liu B: Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol. 5:593–605. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P and Shuai K: Specific inhibition of STAT-3 signal transduction by PIAS3. Science. 278:1803–1805. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Liu B, Gross M, ten Hoeve J and Shuai K: A transcriptional corepressor of Stat1 with an essential LXXLL signature motif. Proc Natl Acad Sci USA. 98:3203–3207. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD and Shuai K: Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci USA. 95:10626–10631. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Verhoeven Y, Tilborghs S, Jacobs J, De Waele J, Quatannens D, Deben C, Prenen H, Pauwels P, Trinh XB, Wouters A, et al: The potential and controversy of targeting STAT family members in cancer. Semin Cancer Biol. Oct 9–2019.doi: 10.1016/j.semcancer.2019.10.002 (Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
|
Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G, et al: Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 10:105–115. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Huynh J, Etemadi N, Hollande F, Ernst M and Buchert M: The JAK/STAT3 axis: A comprehensive drug target for solid malignancies. Semin Cancer Biol. 45:13–22. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Johnson DE, O'Keefe RA and Grandis JR: Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 15:234–248. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H and Karin M: Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 140:197–208. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Jones SA, Scheller J and Rose-John S: Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 121:3375–3383. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L and Karin M: IL-6 and STAT3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 15:103–113. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T, Canli O, Schwitalla S, et al: Gp130-mediated STAT3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 15:91–102. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Schiechl G, Bauer B, Fuss I, Lang SA, Moser C, Ruemmele P, Rose-John S, Neurath MF, Geissler EK, Schlitt HJ, et al: Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages. J Clin Invest. 121:1692–1708. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Yang J, Qian J, Li H, Romaguera JE, Kwak LW, Wang M and Yi Q: Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 120:3783–3792. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Schafer ZT and Brugge JS: IL-6 involvement in epithelial cancers. J Clin Invest. 117:3660–3663. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, et al: IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest. 117:3988–4002. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, Zheng YL, Bowman ED, Engels EA, Caporaso NE and Harris CC: Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst. 103:1112–1122. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H and Murai M: Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res. 6:2702–2706. 2000.PubMed/NCBI | |
|
Reynaud D, Pietras E, Barry-Holson K, Mir A, Binnewies M, Jeanne M, Sala-Torra O, Radich JP and Passegué E: IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell. 20:661–673. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ancrile B, Lim KH and Counter CM: Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 21:1714–1719. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Gyamfi J, Lee YH, Eom M and Choi J: Interleukin-6/STAT3 signalling regulates adipocyte induced epithelial-mesenchymal transition in breast cancer cells. Sci Rep. 8:88592018. View Article : Google Scholar : PubMed/NCBI | |
|
Gao X, Liu X, Lu Y, Wang Y, Cao W, Liu X, Hu H and Wang H: PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation. Breast Cancer. 26:663–671. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MS, Lee WS, Jeong J, Kim SJ and Jin W: Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer. Oncotarget. 6:40158–40171. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Xin H, Lu R, Lee H, Zhang W, Zhang C, Deng J, Liu Y, Shen S, Wagner KU, Forman S, et al: G-protein-coupled receptor agonist BV8/prokineticin-2 and STAT3 protein form a feed-forward loop in both normal and malignant myeloid cells. J Biol Chem. 288:13842–13849. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A, Kortylewski M, Horne D, Somlo G, Forman S, et al: STAT-3-induced S1PR1 expression is crucial for persistent STAT-3 activation in tumors. Nat Med. 16:1421–1428. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, Garland WA, Lu Y, Yu S, Hall HS, et al: Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell. 9:225–238. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kawamori T, Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Bielawski J, Hannun YA and Obeid LM: Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J. 23:405–414. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sarkar S, Maceyka M, Hait NC, Paugh SW, Sankala H, Milstien S and Spiegel S: Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells. FEBS Lett. 579:5313–5317. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Deng J, Wang L, Lee H, Armstrong B, Scuto A, Kowolik C, Weiss LM, Forman S and Yu H: S1PR1 is an effective target to block STAT-3 signaling in activated B cell-like diffuse large B-cell lymphoma. Blood. 120:1458–1465. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ponnusamy S, Meyers-Needham M, Senkal CE, Saddoughi SA, Sentelle D, Selvam SP, Salas A and Ogretmen B: Sphingolipids and cancer: Ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol. 6:1603–1624. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Priceman SJ, Shen S, Wang L, Deng J, Yue C, Kujawski M and Yu H: S1PR1 is crucial for accumulation of regulatory T cells in tumors via STAT3. Cell Rep. 6:992–999. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Eyking A, Ey B, Rünzi M, Roig AI, Reis H, Schmid KW, Gerken G, Podolsky DK and Cario E: Toll-like receptor 4 variant D299G induces features of neoplastic progression in Caco-2 intestinal cells and is associated with advanced human colon cancer. Gastroenterology. 141:2154–2165. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Tye H, Kennedy CL, Najdovska M, McLeod L, McCormack W, Hughes N, Dev A, Sievert W, Ooi CH, Ishikawa TO, et al: STAT-3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell. 22:466–478. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ochi A, Graffeo CS, Zambirinis CP, Rehman A, Hackman M, Fallon N, Barilla RM, Henning JR, Jamal M, Rao R, et al: Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest. 122:4118–4129. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wild CA, Brandau S, Lindemann M, Lotfi R, Hoffmann TK, Lang S and Bergmann C: Toll-like receptors in regulatory T cells of patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 136:1253–1259. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Liang F, Ren C, Wang J, Wang S, Yang L, Han X, Chen Y, Tong G and Yang G: The crosstalk between STAT3 and p53/RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug/MAPK/PI3K/AKTmediated regulation of EMT and autophagy. Oncogenesis. 8:592019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang JR, Shen GN, Luo YH, Piao XJ, Zhang Y, Wang H, Li JQ, Xu WT, Zhang Y, Wang SN, et al: 2-(4-methoxyphenylthio)-5,8-dimethoxy-1,4-naphthoquinone induces apoptosis via ROS-mediated MAPK and STAT3 signaling pathway in human gastric cancer cells. J Chemother. 31:214–226. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lakshmanachetty S, Balaiya V, High WA and Koster MI: Loss of TP63 promotes the metastasis of head and neck squamous cell carcinoma by activating MAPK and STAT3 signaling. Mol Cancer Res. 17:1279–1293. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ahmed ST and Ivashkiv LB: Inhibition of IL-6 and IL-10 signaling and Stat activation by inflammatory and stress pathways. J Immunol. 165:5227–5237. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Yan K, Xu X, Wu T, Li J, Cao G, Li Y and Ji Z: Knockdown of PYCR1 inhibits proliferation, drug resistance and EMT in colorectal cancer cells by regulating STAT3-Mediated p38 MAPK and NF-kB signalling pathway. Biochem Biophys Res Commun. 520:486–491. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Benekli M, Baumann H and Wetzler M: Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol. 27:4422–4432. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang S, Yang Z, Bao W, Liu L, You Y, Wang X, Shao L, Fu W, Kou X, Shen W, et al: SNX10 (sorting nexin 10) inhibits colorectal cancer initiation and progression by controlling autophagic degradation of SRC. Autophagy. 4:1–15. 2019. View Article : Google Scholar | |
|
Liu CY, Huang TT, Chu PY, Huang CT, Lee CH, Wang WL, Lau KY, Tsai WC, Chao TI, Su JC, et al: The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells. Exp Mol Med. 49:e3662017. View Article : Google Scholar : PubMed/NCBI | |
|
Yu H, Pardoll D and Jove R: STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer. 9:798–809. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jarnicki A, Putoczki T and Ernst M: Stat3: Linking inflammation to epithelial cancer-more than a ‘gut’ feeling? Cell Div. 5:142010. View Article : Google Scholar : PubMed/NCBI | |
|
Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI | |
|
Huang DC, Adams JM and Cory S: The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J. 17:1029–1039. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Reed JC: Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol. 11:68–75. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Welcker M, Lukas J, Strauss M and Bartek J: Enhanced protein stability: A novel mechanism of D-type cyclin over-abundance identified in human sarcoma cells. Oncogene. 13:419–425. 1996.PubMed/NCBI | |
|
Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL and Xie K: STAT-3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 22:319–329. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I and Bromberg JF: Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by STAT-3-C. Proc Natl Acad Sci USA. 101:10602–10607. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al: Constitutive STAT-3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Lieblein JC, Ball S, Hutzen B, Sasser AK, Lin HJ, Huang TH, Hall BM and Lin J: STAT3 can be activated through paracrine signaling in breast epithelial cells. BMC Cancer. 8:3022008. View Article : Google Scholar : PubMed/NCBI | |
|
Lin J, Jin X, Rothman K, Lin HJ, Tang H and Burke W: Modulation of signal transducer and activator of transcription 3 activities by p53 tumor suppressor in breast cancer cells. Cancer Res. 62:376–380. 2002.PubMed/NCBI | |
|
Li L, Tang W, Wu X, Karnak D, Meng X, Thompson R, Hao X, Li Y, Qiao XT, Lin J, et al: HAb18G/CD147 promotes pSTAT-3-mediated pancreatic cancer development via CD44s. Clin Cancer Res. 19:6703–6715. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Xu W, Sun D, Wang Y, Zheng X, Li Y, Xia Y and Teng Y: Inhibitory effect of microRNA-608 on lung cancer cell proliferation, migration, and invasion by targeting BRD4 through the JAK2/STAT3 pathway. Bosn J Basic Med Sci. Oct 17–2019.doi: 10.17305/bjbms.2019.4216 (Epub ahead of print). View Article : Google Scholar | |
|
Sun R, Liu Z, Qiu B, Chen T, Li Z, Zhang X, Xu Y and Zhang Z: Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway. EBioMedicine. 47:142–155. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sun C and Bernards R: Feedback and redundancy in receptor tyrosine kinase signaling: Relevance to cancer therapies. Trends Biochem Sci. 39:465–474. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Li G, Zhao L, Li W, Fan K, Qian W, Hou S, Wang H, Dai J, Wei H and Guo Y: Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. Oncotarget. 5:8317–8329. 2014.PubMed/NCBI | |
|
Song H, Wang R, Wang S and Lin J: A low-molecular-weight compound discovered through virtual database screening inhibits STAT-3 function in breast cancer cells. Proc Natl Acad Sci USA. 102:4700–4705. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Chen CL, Cen L, Kohout J, Hutzen B, Chan C, Hsieh FC, Loy A, Huang V, Cheng G and Lin J: Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer. 7:782008. View Article : Google Scholar : PubMed/NCBI | |
|
Miyoshi K, Takaishi M, Nakajima K, Ikeda M, Kanda T, Tarutani M, Iiyama T, Asao N, DiGiovanni J and Sano S: STAT3 as a therapeutic target for the treatment of psoriasis: A clinical feasibility study with STA-21, a STAT3 inhibitor. J Invest Dermatol. 131:108–117. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Park JS, Kwok SK, Lim MA, Kim EK, Ryu JG, Kim SM, Oh HJ, Ju JH, Park SH, Kim HY and Cho ML: STA-21, a promising STAT-3 inhibitor that reciprocally regulates Th17 and Treg cells, inhibits osteoclastogenesis in mice and humans and alleviates autoimmune inflammation in an experimental model of rheumatoid arthritis. Arthritis Rheumatol. 66:918–929. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C and Lin J: STAT-3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 71:7226–7237. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lin L, Benson DM Jr, DeAngelis S, Bakan CE, Li PK, Li C and Lin J: A small molecule, LLL12 inhibits constitutive STAT-3 and IL-6-induced STAT-3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells. Int J Cancer. 130:1459–1469. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Li PK, Li C and Lin J: Inhibition of STAT-3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J Biol Chem. 285:27429–27439. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Jain R, Kulkarni P, Dhali S, Rapole S and Srivastava S: Quantitative proteomic analysis of global effect of LLL12 on U87 cell's proteome: An insight into the molecular mechanism of LLL12. J Proteomics. 113:127–142. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zuo M, Li C, Lin J and Javle M: LLL12, a novel small inhibitor targeting STAT-3 for hepatocellular carcinoma therapy. Oncotarget. 6:10940–10949. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bid HK, Kibler A, Phelps DA, Manap S, Xiao L, Lin J, Capper D, Oswald D, Geier B, DeWire M, et al: Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma. Clin Cancer Res. 19:6716–6729. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence NJ, et al: Selective chemical probe inhibitor of STAT3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA. 104:7391–7396. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Yue P, Fletcher S, Zhao W, Gunning PT and Turkson J: A novel small-molecule disrupts STAT-3 SH2 domain-phosphotyrosine interactions and STAT-3-dependent tumor processes. Biochem Pharmacol. 79:1398–1409. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Fletcher S, Singh J, Zhang X, Yue P, Page BD, Sharmeen S, Shahani VM, Zhao W, Schimmer AD, Turkson J and Gunning PT: Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: Potent in vitro and tumor cell activities. Chembiochem. 10:1959–1964. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT, Paladino D, Zhao J, Chen Y, Gunning PT and Turkson J: Orally bioavailable small-molecule inhibitor of transcription factor Stat-3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci USA. 109:9623–9628. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Resetca D, Haftchenary S, Gunning PT and Wilson DJ: Changes in signal transducer and activator of transcription 3 (STAT-3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization. J Biol Chem. 289:32538–32547. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Haftchenary S, Luchman HA, Jouk AO, Veloso AJ, Page BD, Cheng XR, Dawson SS, Grinshtein N, Shahani VM, Kerman K, et al: Potent targeting of the STAT 3 protein in brain cancer stem cells: A promising route for treating glioblastoma. ACS Med Chem Lett. 4:1102–1107. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao C, Xiao H, Wu X, Li C, Liang G, Yang S and Lin J: Rational combination of MEK inhibitor and the STAT-3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells. Oncotarget. 6:14472–14487. 2015.PubMed/NCBI | |
|
Xiao H, Bid HK, Jou D, Wu X, Yu W, Li C, Houghton PJ and Lin J: A novel small molecular STAT-3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells. J Biol Chem. 290:3418–3429. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hayakawa F, Sugimoto K, Harada Y, Hashimoto N, Ohi N, Kurahashi S and Naoe T: A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J. 3:e1662013. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MJ, Nam HJ, Kim HP, Han SW, Im SA, Kim TY, Oh DY and Bang YJ: OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT-3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 335:145–152. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yu W, Xiao H, Lin J and Li C: Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design. J Med Chem. 56:4402–4412. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Huang W, Dong Z, Chen Y, Wang F, Wang CJ, Peng H, He Y, Hangoc G, Pollok K, Sandusky G, et al: Small-molecule inhibitors targeting the DNA-binding domain of STAT-3 suppress tumor growth, metastasis and STAT-3 target gene expression in vivo. Oncogene. 35:8022016. View Article : Google Scholar : PubMed/NCBI | |
|
Huang W, Dong Z, Wang F, Peng H, Liu JY and Zhang JT: A small molecule compound targeting STAT-3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion. ACS Chem Biol. 9:1188–1196. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ogura M, Uchida T, Terui Y, Hayakawa F, Kobayashi Y, Taniwaki M, Takamatsu Y, Naoe T, Tobinai K, Munakata W, et al: Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. Cancer Sci. 106:896–901. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wong AL, Soo RA, Tan DS, Lee SC, Lim JS, Marban PC, Kong LR, Lee YJ, Wang LZ, Thuya WL, et al: Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol. 26:998–1005. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Brambilla L, Genini D, Laurini E, Merulla J, Perez L, Fermeglia M, Carbone GM, Pricl S and Catapano CV: Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT-3). Mol Oncol. 9:1194–1206. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Oh DY, Lee SH, Han SW, Kim MJ, Kim TM, Kim TY, Heo DS, Yuasa M, Yanagihara Y and Bang YJ: Phase I study of OPB-31121, an Oral STAT-3 inhibitor, in patients with advanced solid tumors. Cancer Res Treat. 47:607–615. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Okusaka T, Ueno H, Ikeda M, Mitsunaga S, Ozaka M, Ishii H, Yokosuka O, Ooka Y, Yoshimoto R, Yanagihara Y and Okita K: Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor in patients with advanced hepatocellular carcinoma. Hepatol Res. 45:1283–1291. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Takakura A, Nelson EA, Haque N, Humphreys BD, Zandi-Nejad K, Frank DA and Zhou J: Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. Hum Mol Genet. 20:4143–4154. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, et al: Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 379:645–648. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Jin J, Guo Q, Xie J, Jin D and Zhu Y: Combination of MEK inhibitor and the JAK2-STAT3 pathway inhibition for the therapy of colon cancer. Pathol Oncol Res. 25:769–775. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Joung YH, Na YM, Yoo YB, Darvin P, Sp N, Kang DY, Kim SY, Kim HS, Choi YH, Lee HK, et al: Combination of AG490, a Jak2 inhibitor, and methylsulfonylmethane synergistically suppresses bladder tumor growth via the Jak2/STAT3 pathway. Int J Oncol. 44:883–895. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Pandey MK, Sung B and Aggarwal BB: Betulinic acid suppresses STAT-3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int J Cancer. 127:282–292. 2010.PubMed/NCBI | |
|
Su D, Gao YQ, Dai WB, Hu Y, Wu YF and Mei QX: Helicteric acid, oleanic acid, and betulinic acid, three triterpenes from helicteres angustifolia L., Inhibit proliferation and induce apoptosis in HT-29 colorectal cancer cells via suppressing NF-κB and STAT3 signaling. Evid Based Complement Alternat Med. 2017:51807072017. View Article : Google Scholar : PubMed/NCBI | |
|
Nardini M, Pisu P, Gentili V, Natella F, Di Felice M, Piccolella E and Scaccini C: Effect of caffeic acid on tert-butyl hydroperoxide-induced oxidative stress in U937. Free Radic Biol Med. 25:1098–1105. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Tapiero H, Tew KD, Ba GN and Mathe G: Polyphenols: Do they play a role in the prevention of human pathologies? Biomed Pharmacother. 56:200–207. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Nardini M, Leonardi F, Scaccini C and Virgili F: Modulation of ceramide-induced NF-kappaB binding activity and apoptotic response by caffeic acid in U937 cells: Comparison with other antioxidants. Free Radic Biol Med. 30:722–733. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Jung JE, Kim HS, Lee CS, Park DH, Kim YN, Lee MJ, Lee JW, Park JW, Kim MS, Ye SK and Chung MH: Caffeic acid and its synthetic derivative CADPE suppress tumor angiogenesis by blocking STAT-3-mediated VEGF expression in human renal carcinoma cells. Carcinogenesis. 28:1780–1787. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Rajendran P, Li F, Shanmugam MK, Kannaiyan R, Goh JN, Wong KF, Wang W, Khin E, Tergaonkar V, Kumar AP, et al: Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT-3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev Res (Phila). 5:631–643. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kannaiyan R, Hay HS, Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Sharma A, Kumar AP, et al: Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-KB and STAT-3 regulated gene products in multiple myeloma cells. Br J Pharmacol. 164:1506–1521. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Pang X, Yi Z, Zhang J, Lu B, Sung B, Qu W, Aggarwal BB and Liu M: Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res. 70:1951–1959. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lu Z, Jin Y, Qiu L, Lai Y and Pan J: Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett. 290:182–191. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Weissenberger J, Priester M, Bernreuther C, Rakel S, Glatzel M, Seifert V and Kögel D: Dietary curcumin attenuates glioma growth in a syngeneic mouse model by inhibition of the JAK1,2/STAT-3 signaling pathway. Clin Cancer Res. 16:5781–5795. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Li F, Fernandez PP, Rajendran P, Hui KM and Sethi G: Diosgenin, a steroidal saponin, inhibits STAT-3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett. 292:197–207. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Ahn KS, Kumar AP and Sethi G: Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1. J Cell Physiol. 227:2184–2195. 2012. View Article : Google Scholar : PubMed/NCBI |
